Treatment Options for Atrial Fibrillation Refractory to Metoprolol

Rate Control Options

The American Heart Association recommends adding digoxin to metoprolol for combination therapy to control heart rate both at rest and during exercise in patients with atrial fibrillation refractory to metoprolol 1, 2
The European Society of Cardiology recommends switching to a non-dihydropyridine calcium channel blocker, such as diltiazem or verapamil, as first-line agents for rate control in patients with preserved left ventricular function (LVEF >40%) 3, 4
Combination therapy with different rate-controlling agents should be considered if a single agent does not achieve the necessary heart rate target, according to the European Heart Journal 4

The American College of Cardiology recommends considering switching to a rhythm control strategy when rate control is ineffective and symptoms persist, with options including class IC antiarrhythmics, such as flecainide or propafenone, for patients without structural heart disease 6
Electrical cardioversion is recommended for symptomatic patients when pharmacological approaches fail, according to the European Heart Journal and Circulation 2, 3
Catheter ablation can be considered as a second-line option if antiarrhythmic drugs fail to control AF, or as a first-line option in patients with paroxysmal AF, as stated in the European Heart Journal 7

For patients with preserved LVEF (≥40%), the European Heart Journal recommends trying a non-dihydropyridine calcium channel blocker (diltiazem or verapamil) and, if ineffective, adding digoxin for combined therapy 1, 2, 3, 4
For patients with reduced LVEF (<40%), adding digoxin to the beta-blocker regimen is recommended, with consideration of amiodarone for rate control if combination therapy is ineffective, according to the European Heart Journal and Circulation 2, 3, 4, 8

Anticoagulation should be maintained regardless of rate or rhythm control strategy, based on stroke risk assessment, as recommended by the European Heart Journal 7
Non-dihydropyridine calcium channel blockers should be used cautiously in patients with heart failure due to their negative inotropic effects, according to Circulation 9
Certain combinations, such as digoxin, adenosine, and non-dihydropyridine calcium channel antagonists, should be avoided in patients with Wolff-Parkinson-White syndrome and pre-excited AF, as they can be potentially harmful, as stated in Circulation 1